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Abstract
Background: Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold standard. Non-invasive
techniques, liver stiffness measurements (LSM) and biomarkers [FibroTestH (FT)], are widely used in countries where they are
available. The aim was to identify factors associated with LSM accuracy using FT as a non-invasive endpoint and vice versa.
Methods: The proof of concept was taken using the manufacturers recommendations for excluding patients at high risk of
false negative/positive. The hypothesis was that the concordance between LSM and FT, would be improved by excluding
high-risk patients. Thereafter, the impact of potential variability factors was assessed by the same methods. Liver biopsy and
independent endpoints were used to validate the results.
Results: Applying manufacturers’ recommendations in 2,004 patients increased the strength of concordance between LSM
and FT (P,0.00001). Among the 1,338 patients satisfying recommendations, the methodology identified a significant LSM
operator effect (P=0.001) and the following variability factors (all P,0.01), related to LSM: male gender, older age, and
NAFLD as a cause of liver disease. Biopsy confirmed in 391 patients these results.
Conclusion: This study has validated the concept of using the strength of concordance between non-invasive estimates of
liver fibrosis for the identification of factors associated with variability and precautions of use.
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Introduction
A major clinical challenge is finding the best means of
evaluating and managing the increasing numbers of patients with
chronic liver disease [1]. Liver biopsy, due to its risks and
limitations, is no longer considered mandatory as the first-line
indicator of liver injury, and several markers have been developed
as non-invasive alternatives [1,2].
The true liver disease status, the ‘‘gold standard’’ is the
histological analysis of nearly the entire liver [3]. Therefore the
definitive diagnosis is impossible to obtain in routine practice, and
the liver biopsy, an ‘‘imperfect gold standard’’ [4], is used as a
standard against which new tests are evaluated [5,6].
The assessment of liver fibrosis by non-invasive techniques,
biomarkers [FibroTestH (FT)] [7,8] and liver stiffness measure-
ments (LSM) by FibroscanH [9,10] is now widely done in countries
where these techniques are available and approved.[11,12] It is
therefore essential to identify factors associated with variability of
these imperfect gold standards to reduce the risk of false positive
and false negative.
The aim was to propose an original methodology for identifying
factors associated with the variability of these techniques.
Methods
Concept
We developed the following concept: when there are no perfect
gold standards but only imperfect gold standards for estimating the
truth, the measurement of the strength of the concordance
between these imperfect gold standards could be used as a tool for
identifying factors of variability.
Any variability factor of one test should impact the strength of
the association between the two tests assuming that this variability
factor is not also associated with the other test (independent tests).
The following examples illustrate this concept. For estimating
liver fibrosis stages, LSM and FT have been considered as two
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of LSM, [13–14] is the total number of valid measurements.
Therefore if subjects with a number of measurements below the
recommended number (n=10) are included, the strength of
association between LSM and FT fibrosis estimates should
decrease in comparison with a population excluding these subjects.
The tests are independent as there is no rationale suggesting that
the number of valid measurements could be associated with the
FT estimate.
Similarly one variability factor of FT, [7–8,15] is the presence of
Gilbert’s syndrome (genetic increase of total bilirubin) that induces
a risk of FT false positive as bilirubin is a component of FT.
Therefore if subjects with Gilbert syndrome are included, the
strength of association between LSM and FT should decrease in
comparison with a population excluding these subjects. The tests
are independent as there is no rational suggesting that the presence
of Gilbert syndrome could be related to the LSM estimate.
Proof of concept
To validate this concept we compared the strength of
concordance between LSM and FT, for the diagnosis of advanced
fibrosis stage, between a population including only subjects who
fulfilled the quality criteria as recommended by the manufacturer
(low risk profile of false negatives/positives) and a population not
fulfilling these quality criteria (high risk of false negatives/positives).
For LSM the recommended criteria were: success rate greater
than 60% (SR60), at least 10 valid liver stiffness measurements
(V10) and interquartile range/median LSM,30% (IQR30) [12–
15]; For FT, these were: a security algorithm profile excluding
Gilbert’s disease, hemolysis, acute inflammation profiles and
extremes values (one percentile) of FT components [8,12,16].
Potential factors of variability
The following potential factors of LSM variability were tested:
operator effect, male gender, steatosis (presumed with SteatoTest),
necroinflammatory activity (presumed with ActiTest), normal
transaminases ALT, anthropometric factors (BMI, abdominal
and thoracic folds, waist circumference), cause of liver disease and
ethnic origin.
The following potential factors of FT variability were tested:
normal transaminases ALT, cause of liver disease and ethnic origin.
Validation of results
Liver biopsy was used to confirm the results observed with the
proposed methods.
In order to attribute the cause of ‘‘cirrhosis discordance’’
between FT and LSM, all the cases with cirrhosis predicted by
only one method were reviewed as previously published [5].
Biochemical markers
FibroTest, ActiTest and SteatoTest (Biopredictive, Paris,
France) were performed according to published recommendations.
[25,8,16–18]
Liver stiffness measurements
Patients were studied using the non-invasive method of transient
elastography (Fibroscan, Echosens, Paris, France). The stiffness
results are expressed in kilopascals (kPa). The technique was
performed by trained (more than 100 measurements) senior
hepatologists (operator), blinded to all other characteristics, and
according to the manufacturers’ recommendations. The following
recommended cutoffs were used: 5.1, 8.8, 9.5 and 14.5 kPa for the
F0, F1, F2, F3 and F4 staging respectively [14]. We took 8.8 as
cutoff for advanced fibrosis (defined as F2 or greater) and not
7.1 kPa [9] as the 95% percentiles of healthy population is 7.8 for
female and 8.0 for male [19].
Biopsy
Staging and grading were performed blinded to non-invasive
methods, according to METAVIR scoring system [20] and
according to Brunt et al for NAFLD [21] by one experienced
pathologist.
Statistical analysis
The strength of concordance between LSM and FT was
assessed using six methods, three categorical [the area under the
receiver operating characteristic curve (AUC), the kappa reliability
test (K) for 2 (K2) fibrosis stages], two quantitative [Spearman
coefficient of correlation (R), with partial correlation (pR) when
necessary, the intraclass coefficient of correlation (ICC)] and one
mixed (the regression curve randomization test) [22–27].
Concordance analyses were performed with NCSS software
(Kaysville, Utah, USA) [27].
The program ‘‘TAGS’’ was used for the evaluation of FT and
LSM accuracy, in the absence of a perfect gold standard [28]. The
model used two populations comparing FT and LSM, without the
perfect disease status, the present data set (n=1,109 patients) and
the data published by Castera et al (n=183)[9], and two disease
free reference populations (925 blood donors and 429 healthy
subjects) [17,19].
A sensitivity analysis has been performed using the LSM 7.1
cutoff [9] also used for advanced fibrosis, instead of 8.8 kPa [14].
Details of methods are given in supporting information file Text S1.
Because of the number of statistical comparisons and in order to
decrease the risk of false positive conclusion, a P value lower than
0.01 using three different concordance statistical methods were
needed to conclude at a significant difference.
Results
The database included 2,004 consecutive patients who under-
went simultaneously LSM and FT (Table 1) in our center between
June 2005 and April 2007.
A total of 604 (30%) not fulfilled the recommended criteria for
LSM interpretation, 88 (4%) not fulfilled the criteria for FT
interpretation and 1338 (67%) fulfilled both criteria. Patients with
non-interpretable LSM were older, more often female, and had
higher weight, BMI, and abdominal and thoracic folds in
comparison with patients with interpretable LSM (Table 1 and
supporting Table S1).
Proof of concept
The manufacturers’ recommended criteria were all associated
with the strength of concordance between FT and LSM. (Table 2
and supporting Table S2) The proof of concept was validated, as
applying the manufacturers’ recommendations significantly in-
creased the strength of concordance between LSM and FT, using
all statistical methods (from P=0.04 to P,0.00001).
Factors associated with strength of concordance
A significant operator effect was identified with weaker
concordance than all the other operators in the population
without high-risk profile (Figure 1). After excluding the 375
patients analyzed by this operator the strength of concordance was
significantly higher in the 1,109 remaining patients. In the pre-
included population this operator had a higher percentage of LSM
high-risk profile 36% (135/375) vs 29% (469/1629; P=0.006)
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LSM.30% observed in 25% (94/375) vs 18% (287/1629;
P=0.0009) among the other operators. The percentages of other
risk factors were not different including the number of valid
measurements, success rate, FT risk profile, previous experience of
LSM, and prevalence of possible risk factors (data not shown).
Among the 1,109 patients with homogeneous operators and
recommended criteria, the following factors were significantly
associated with lower strength of concordance using at least three
methods and protected for multiple testing: older age (Kap-
pa=0.37 if 50 years or older versus kappa=0.50 if younger),
NAFLD as a cause of chronic liver disease (Kappa=0.24 for
NAFLD versus kappa=0.40 for other disease), the absence of
steatosis presumed with SteatoTest (Kappa=0.38 in the absence
of steatosis and kappa=0.59 in the presence of steatosis; inverse
than the prior hypothesis).
The following factors were associated with lower strength of
concordance (only for one or two methods or P value greater than
0.01): male gender, BMI greater than 30 kg/m2, higher weight,
abdominal fold .30 mm, thoracic fold .15 mm, higher waist
circumference in male, African ethnic origin, and non-elevated
ALT values. There was no impact on the strength of concordance
for height, and daily alcohol consumption (supporting Table S3).
Validation using liver biopsy
A total of 391 patients had previously undergone liver biopsy.
These patients were not different than patients without biopsy
(Table 1). The median time between biopsy and LSM was 4 years,
with 25% being performed within the previous year. Median
biopsy length was 16 mm. Liver biopsy used as an imperfect gold
standard confirmed the diagnostic value of LSM [AUROC=0.66
(0.60–0.71)] and FT [AUROC=0.75 (0.70–0.79)] for predicting
advanced fibrosis. (Table 3)
Patients with recommended criteria had a significantly higher
LSM accuracy [n=266 AUROC=0.72 (0.65–0.78) ] than
patients without these criteria [n=125; AUROC=0.54 (0.42–
0.64); P=0.008)]. FT had the same significant diagnostic accuracy
among patients with or without LSM recommended criteria
[AUROC=0.79 vs 0.72]. The same results were obtained using
the other statistical methods (Supporting Table S4).
Concordance analysis among patients with
recommended criteria
Concordances between LSM, FT and biopsy in patients with
recommended criteria (n=266) are detailed in Figure 2 and in
supporting Text S2.
LSM and FT, using biopsy as a reference, had similar accuracy
with a trend in favor of FT: AUROC (0.72 vs 0.79;P=0.12),
kappa in 2 classes (0.22 vs 0.37; P=0.03). The mean fibrosis stage
presumed using biopsy (1.7; 95%CI 1.6–1.9) was higher than the
mean presumed with LSM using 8.8 kPa cutoff (1.4; 95%CI 1.3–
1.6; P=0.0008), but not different than the mean presumed with
LSM using 7.1 kPa cutoffs (1.7;1.5–1.8;P=0.68) and lower than
those presumed with FT (2.0;1.8–2.2; P=0.004).
Factors associated with strength of concordance
A total of 57 patients with biopsy were assessed with the
previously identified LSM high-risk operator; there was no
difference in LSM accuracy vs the other operators. The IQR/
LSM was 1.5, no different than in the other operators (1.4) but
lower than that observed among the 375 patients (with or without
biopsy) analyzed by this operator (3.0).
The following factors were associated (not significantly) with
lower accuracy of LSM vs FT: BMI.27 kg/m2 (P=0.04),
abdominal fold .30 mm (P=0.06), and thoracic fold .15 mm
(P=0.08).
Analyses and validation of discordance cases with
presumed cirrhosis (Supporting Table S5)
Among the 53 patients with non-advanced fibrosis with LSM
and presumed cirrhosis with FT the failure was attributed to LSM
(false negative) in 29 cases, to FT (false positive) in four. Among the
17 patients with presumed cirrhosis using LSM and non-advanced
fibrosis using FT, the failure was attributed to LSM in two cases
and to FT in seven.
Evaluation of accuracy, in the absence of a gold standard
The best global model with coherent estimates of tests’ accuracy
for the diagnosis of advanced fibrosis was the model using the
Table 1. Characteristics of included patients.
Characteristics
Number of patients 1338
Age at serum, years, mean (SD) 50 (13)
Male (%) 822 (61%)
Ethnic origin
Caucasian 956 (71.5%)
Asian 100 (7.5%)
North African 140 (10.5%)
Other African 142 (10.5%)
Anthropometric data$
Height m 1.7 (0.1)
Weight kg 70 (14)
BMI, kg/m2 24 (4)
Abdominal fold mm 21 (12)
Thoracic fold mm 12 (7)
Waist circumference cm 86 (12)
Daily alcohol .=30 g/day 58 (4%)
Diagnosis
Chronic disease 100%
HCV 517 (39%)
HBV 255 (19%)
NAFLD 168 (13%)
HIV coinfection 112 (8%)
ALD 32 (2%)
Other 99 (7%)
Unknown 155 (12%)
Biochemistry
ALT IU/L 71 (204)
AST IU/L 50 (41)
Cholesterol mmol/L 4.7 (1)
Glucose mmol/L 5.3 (1.8)
Triglycerides mmol/L 1.2 (0.8)
FibroTest 0.43 (0.27)
ActiTest 0.35 (0.26)
SteatoTest 0.35 (0.23)
doi:10.1371/journal.pone.0003857.t001
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between expected and observed specificities and sensitivities (3
degree of freedom, deviance=3; P=0.44). The estimated
specificities were for FT 100% and LSM 96%, and sensitivities
were for FT 86% and LSM 48%. For the cutoff 7.1 kPa, the
model fit also but less well (3 degree of freedom, deviance=6;
P=0.10). The estimated specificities were for FT 100% and LSM
81% and sensitivities were FT 87% and LSM 67% (Supporting
Text S3).
Sensitivity analyses of manufacturers’ recommendations
(Supporting Table S6)
The decreases of cutoffs significantly worsen the concordance
strength, in all methods.
The increase of success rate to 100% (versus 60%) increased
concordance rates but decreased applicability by 50%. Increasing
the cutoff of IQR/LSM at 20% instead of 30% did not increase
the strength of concordance when the high-risk operator had been
excluded.
Table 2. Proof of concept: manufacturers’ risk factors of false positives/negatives are associated with strength of concordance
between FibroTest (FT) and liver stiffness measurements (LSM).
Method assessing concordance
Characteristics
(number patients) AUROC* Kappa 2 Kappa 3 Spearman
Intra Class
Coefficient Curve fitting
Advanced versus non
advanced fibrosis
Advanced versus
non advanced
fibrosis
F0F1 vs
F2F3 vs F4
FT vs LSM FT vs LSM Curve inequality
Mean (95% CI)
Significance
Kappa Mean (se) Mean (se) Mean (95% CI) Mean (95% CI) Linear-Linear Model
F-test R2
All patients (2004) 0.72 (0.70–0.75) 0.38 (0.02) 0.29 (0.02) 0.44 (0.41–0.48) 0.46 (0.42–0.49) 0.21
Manufacturer risk
factors **
P,0.0001 P=0.01 P=0.04 P=0.001 P=0.001 P,0.00001
Yes (666) 0.63 (0.59–0.67) 0.29 (0.04) 0.20 (0.03) 0.27 (0.20–0.34) 0.19 (0.12–0.26) 0.09
No (1338) 0.78 (0.76–0.81) 0.42 (0.03) 0.33 (0.02) 0.55 (0.51–0.59) 0.52 (0.48–0.56) 0.34
High risk Elastography P,0.0001 P=0.08 P=0.003 P=0.001 P,0.0001 P,0.00001
Yes (604) 0.63 (0.58–0.68) 0.32 (0.04) 0.21 (0.03) 0.26 (0.19–0.33) 20.04 (20.12–0.04) 0.10
No (1400) 0.78 (0.75–0.80) 0.40 (0.025) 0.32 (0.02) 0.54 (0.51–0.58) 0.47 (0.43–0.51) 0.33
High risk FibroTest P=0.09 P=0.01 P=0.09 P=0.40 P=0.10 P,0.00001
Yes (88) 0.68 (0.55–0.78) 0.15 (0.07) 0.16 (0.06) 0.30 (0.10–0.48) 0.23 (0.02–0.41) 0.11
No (1916) 0.78 (0.75–0.80) 0.39 (0.02) 0.29 (0.016) 0.44 (0.41–0.48) 0.46 (0.37–0.45) 0.22
*FT as enpoint for LSM AUROCs, LSM as endpoint for FT AUROCs.
**If LSM was taken as endpoint same results were observed: AUROC of patients with manufacturer risk factors (n=666) was 0.71 (0.67–0.75) vs 0.81 (0.78–0.84) in
patients without risk factors (n=1338; P=0.0001).
doi:10.1371/journal.pone.0003857.t002
Figure 1. Operator effect. One operator has significantly lower concordance between stiffness measurement and FibroTest than the other
operator (area under the ROC curve=0.70; 95%CI 0.63–0.76, versus 0.80; 95%CI 0.77–0.82; P=0.009).
doi:10.1371/journal.pone.0003857.g001
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Among the 343 patients without fibrosis using FT, LSM was
associated with ST (R=0.23; P=0.00001), still significant after
adjustment for AT (P=0.01) and with AT (P,0.00001), still
significant after adjustment for ST (P=0.003). There were
significant steatosis and activity effects without interaction. The
median LSM was 0.9 kPa higher in patients with presumed
steatosis and 1.1 kPa higher in patients with presumed activity vs
patients without.
When previous biopsy results were used, (Supporting Table S7)
LSM and FT were able to diagnose fibrosis, regardless of the
presence of steatosis or activity. Similar steatosis and activity effects
on LSM were observed as with ST and AT.
Confounding variables
Details are given in supporting Text S5. As expected, LSM and
FT were highly associated with known risk factors of fibrosis,
which could also be variability factors of LSM. LSM, but not FT,
was associated with weight (P,0.000001) and BMI (P=0.000002).
We observed a high association between IQR/LSM and LSM,
R=0.70. Among patients with advanced fibrosis 30% had a non-
recommended dispersion of LSM (IQR/LSM.30%), which was
twice that in patients without advanced fibrosis: 15% (P,0.0001).
Older age was significantly associated with lower concordance
and this could be related to the following more rational factors that
were also significantly associated with age: NAFLD, thoracic fold,
waist circumference, BMI, serum glucose, ST, and AT.
In patients without fibrosis using FT,theLSMwashigherinmale
(6.0 kPa) than in female (5.2 kPa), but there were also a significant
gender differences for confounding factors: BMI and for ST.
Discussion
The aim of this study was not to validate the diagnostic value of
LSM or FT, which have been extensively assessed in numerous
studies and meta-analyses. The aim was to describe an original
method for assessing imperfect gold standards’ variability, in order
to reduce the risk of false positive and false negative in the
diagnosis of liver fibrosis.
This methodology enabled the recommendations of manufac-
turers to be validated. These recommendations must be strictly
followed as inclusion of patients not adhering to the recommended
cutoffs significantly reduces the strength of concordance.
Among the patients satisfying recommendations, the methodology
identified a significant LSM operator effect and several variability
factors, which had been previously suspected increasing the
variability of LSM, using biopsy as a gold standard. In the present
study, the retrospective analysis of previous biopsy results confirmed
both the proof of concept and the identified variability factors.
Limitations of the study
A major limitation of the present study is the absence of
prospective biopsies in all patients, done the same day as LSM and
FT. We used retrospective liver biopsies as an ‘‘imperfect gold
standard’’. The sample size of patients with liver biopsy was much
smaller in comparison with the population with non-invasive
markers, and only 25% were performed within the year of LSM.
However no systematic bias was identified and the characteristics
Table 3. Validation of the proof of concept using liver biopsy: manufacturers’ risk factors of false positive/negative are associated
with strength of concordance between Elastography and Biopsy.
Characteristics (number patients) AUROC
Liver Stiffness FibroTest
Advanced versus non advanced fibrosis Mean (95% CI) Significance Significance FT vs stiffness
All patients (391) 0.66 (0.60–0.71) 0.75 (0.70–0.79) P=0.007
Manufacturer risk factors P=0.008 P=0.83
Yes (125) 0.56 (0.45–0.65) 0.76 (0.65–0.83) P=0.002
None (266) 0.72 (0.65–0.78) 0.74 (0.68–0.80) P=0.54
High risk Elastography P=0.003 P=0.39
Yes (111) 0.54 (0.42–0.64) 0.78 (0.68–0.86) P=0.0002
No (280) 0.73 (0.66–0.78) 0.73 (0.67–0.79) P=0.80
High risk FibroTest P=0.01 P=0.03
Yes (16) 0.88 (0.53–0.98) 0.63 (0.23–0.84) P=0.13
No (375) 0.65 (0.59–0.70) 0.76 (0.70–0.80) P=0.0004
doi:10.1371/journal.pone.0003857.t003
Figure 2. Associations between three estimates of liver fibrosis:
FibroTest, liver stiffness measurements and fibrosis stage at
biopsy, in 266 patients with recommended criteria. Each point
represents the result of biopsy stage using METAVIR scoring system:
white circle F0 (no fibrosis), light grey triangle F1 (portal fibrosis), grey
square F2 (few septa), light black pentagon F3 (many septa) and dark
black hexagon F4 (cirrhosis). These points are distributed according to
FibroTest value on the vertical axis and liver stiffness measurements on
horizontal axis. The first horizontal line is the FibroTest cutoff (0.48) for
stage F2, the second (0.73) for F4. The first vertical line is the stiffness
cutoff (8.8 kPa) for stage F2, the second (14.5 kPa) for F4.
doi:10.1371/journal.pone.0003857.g002
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We acknowledge that, for biomarkers of activity (AT) and steatosis
(ST), the elapsed time between biopsy and LSM could be another
significant variability factor. However, for fibrosis stages, the risk
of very significant changes was small. Simultaneous liver biopsy
cannot be obtained in such large populations, without major bias.
We used multiple methods and multiple tests, but we used
conservative rules to reduce the overall risk of false positive
conclusions. The proof of concept analysis and the main variability
factors for LSM and FT were highly significant at a P value
(P,0.001) lower than the scheduled P value of 0.01 and obtained
with at least three different methods. The significance of analyses
in patients with biopsy was smaller but in the same directions that
in the overall population. The a priori hypothesis and the rational
of factors tested are also important to reduce the risk of false
positive. The main LSM variability factors identified have both a
rational and had been already suspected.
Despite a trend for unifying methods assessing concordance,
they are no specific guidelines for choosing in practice one method
among the six used in the present study [29].
Advantages of the study
A major advantage of the present study was the analysis of two
tests (LSM and FT) simultaneously performed in a large number of
consecutive patients.
Proof of concept
For the proof of concept, manufacturers’ recommendations
were used. The methodology implied recommendations being
independent between LSM and FT. Indeed there was no
relationship between the applicability of FT (mostly related to
Gilbert’s syndrome, hemolysis and acute sepsis) and the applica-
bility of LSM (number of valid LSM, success rate and IQR/LSM).
Sensitivity analyses of manufacturers’ recommendations
Any change in recommendations can have a direct impact on
applicability of LSM, and on the risk of false/positives or
negatives. In the present study LSM was applicable in only 70%
of consecutive patients. The results strongly suggest that it would
be hazardous to decrease the cutoffs of LSM applicability for the
diagnosis of advanced fibrosis as suggested by others [15].
Kettaneh et al suggested that for cirrhosis diagnosis only, five
valid shots could be sufficient, but the impact of IQR/LSM and
success rate had not been assessed [14].
Identifications of variability factors
An operator effect was identified despite experience of over
100 LSM. Interestingly this operator had a significantly higher
IQR/LSM than other operators. Therefore concordance
analyses between LSM and FT could be useful to ‘‘certify’’
the operators.
The previously suspected LSM variability factors were also
identified by the concordance analyses: older age [14,30] male
gender [14,19,30,31], NAFLD as a cause of chronic liver disease
[14,30], overweight [14,19,30], BMI [14,19,30], abdominal fold
[14,30], and thoracic fold [31]. The methodology can be used only
if a variability factor is associated with only one of the two
imperfect gold standards. The main significant factors associated
with LSM variability, operator factor, NAFLD, overweight, BMI,
abdominal fold, and thoracic fold were not associated with FT.
These factors were not associated with FT variability [32]. The
identification of factors associated with the variability of LSM and
FT is complex as most of them were also factors known to be
associated with fibrosis progression.
As with others, we observed a very significant association
between LSM and age, which almost disappeared after adjustment
with metabolic factors. There is no rationale for a direct impact of
age on LSM.
Male gender has already been suspected of being a cause of
LSM increase [19,30,31]. Confounding variables such as BMI,
weight, age and other fibrosis estimates have not been excluded. In
the present study we also found an LSM increase (0.8 kPa) in male
adjusted on fibrosis, but BMI and steatosis could still explain the
difference.
Steatosis is associated with fibrosis and therefore steatosis is at
least indirectly associated with LSM [30,34]. Few studies have
assessed whether steatosis was directly associated with LSM
independent of fibrosis. Kim et al found on a small number of
patients, no significant association between LSM and steatosis
[35]. Fraquelli et al observed that the LSM reproducibility was
significantly reduced in patients with steatosis at biopsy. However
no patients were excluded for IQR.=30% in that study, and
LSM association with steatosis was not detailed. [34]
The present study confirmed that the presence of steatosis
(presumed with ST) was associated with higher presumed fibrosis
stage either with FT or LSM. The present results also suggest that
the presence of steatosis (independently of fibrosis stage) and
related anthropometric factors (waist circumference, abdominal
fold), could be associated with false positive of LSM in patients
without cirrhosis. This is in accordance with the false positive rate
of LSM observed by others [35] in patients with steatosis, using
biopsy as an endpoint. The rational of a risk of false positive could
be an increase of the LSM related to an increase of hepatocytes’
stiffness due to triglycerides droplets.
The present study confirmed that overweight and BMI were
associated with less applicability of LSM [19,33,36] In overweight
or obese patients, the fatty thoracic belt attenuates both elastic
waves and ultrasound rendering liver stiffness measurement
impossible, preventing the risk of false measurement [36].
Activity is associated with fibrosis and therefore activity
necroinflammatory activity grades are at least indirectly associated
with LSM [30,34]. Few studies have assessed if activity was
directly associated with LSM independently of fibrosis. Coco et al
observed that LSM was significantly associated with ALT
(adjusted for fibrosis and steatosis) and with activity [30]. In the
present we observed an association between necroinflammatory
activity and LSM, but less consistent than the association observed
with steatosis. The rationale for activity is unknown and could be a
transient extra cellular matrix, edema or extent of the inflamma-
tory infiltrate of the septa.
Finally from the populations studied, the cutoffs 0.48 for FT and
7.1 kPa for LSM were validated in a global coherent model for the
diagnosis of advanced fibrosis, without using imperfect gold
standard. The LSM accuracy was better using 7.1 cutoff with
sensitivity+specificity=1.68 versus 1.44 for the 8.8 cutoff. FT had
similar and high specificity and sensitivity for both models (sum
1.81 and 1.86). This is the first time that non-invasive biomarkers
have been estimated not using biopsy as a gold standard. The
classical evaluation using biopsy as a gold standard obtained for
LSM 7.1 kPa specificity=89% and sensitivity=67% (sum 1.56)
and for FT 83% and 62% respectively (sum 1.45) [8,9,10]. These
differences are probably mostly explained by the variability of liver
biopsy, the variability in applying manufacturers’ recommenda-
tions and the spectrum bias [3,15,22,23,33].
In conclusion, this study has validated the concept of using the
strength of concordance between two non-invasive estimates of
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variability and precautions of use. Manufacturers’ recommenda-
tions must be strictly followed. There is a need to better define the
upper normal limit value of liver stiffness measurements, as well as
the choice of a consensual cutoff for advanced fibrosis, because of
the risk of false negatives.
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